Literature DB >> 1356961

Pharmacological properties of alpha 1-adrenoceptor-mediated vasoconstrictions in dog and monkey lingual arteries: evidence for subtypes of alpha 1-adrenoceptors.

R Skrbic1, S Chiba.   

Abstract

We examined whether alpha 1-adrenoceptor-mediated vasoconstrictions were due to extra- or intracellular Ca2+ movements, and whether they were subdivided into alpha 1-adrenoceptor subtypes in dog and monkey lingual arteries. The NE-induced vasoconstriction in dog lingual arteries was mostly dependent on Ca2+ influx from the extracellular space, since it was readily blocked by a Ca2+ entry blocker, diltiazem, and the NE-induced response was attenuated approximately 90% in Ca(2+)-free solution. On the other hand, in monkey lingual arteries, diltiazem failed to depress the NE-induced dose-response curve, and the response was attenuated only about 60% in Ca(2+)-free solution. The vasoconstrictor response to 10mg caffeine in normal KHS was almost the same as that to 1 micrograms NE in Ca(2+)-free solution in both kinds of arteries, suggesting that alpha 1-adrenoceptor-mediating vasoconstrictions require a different number of sources of Ca2+ in different blood vessels. Pretreatment of preparations with CEC (an alpha 1B-antagonist) significantly suppressed and shifted the dose-response curve for NE to the right in monkey lingual arteries, but it had no significant effect in dog lingual arteries. However, WB4101 (an alpha 1A-antagonist) showed almost the same potency in blocking vasoconstrictor responses as bunazosin in both kinds of arteries (the pA2 values were not significantly different). Moreover, responses to ME (an alpha 1A-agonist) were blocked by diltiazem as well as by bunazosin and WB4101, while CEC had no blocking effect on ME-induced responses.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356961     DOI: 10.1007/bf01744453

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  37 in total

1.  Comparison of pre- and postsynaptic alpha-adrenoceptor blocking effects of E-643 in the isolated vas deferens of the rat.

Authors:  T Shoji
Journal:  Jpn J Pharmacol       Date:  1981-06

Review 2.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+.

Authors:  K P Minneman
Journal:  Pharmacol Rev       Date:  1988-06       Impact factor: 25.468

3.  What do antagonists tell us about alpha-adrenoceptors?

Authors:  G M Drew
Journal:  Clin Sci (Lond)       Date:  1985       Impact factor: 6.124

4.  Differential interactions of clonidine and methoxamine with the postsynaptic alpha-adrenoceptor of rabbit main pulmonary artery.

Authors:  M I Holck; C H Jones; G Haeusler
Journal:  J Cardiovasc Pharmacol       Date:  1983 Mar-Apr       Impact factor: 3.105

Review 5.  Alpha-adrenoceptor subclassification.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1981       Impact factor: 5.545

6.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

7.  Theoretical bases for vascular selectivity of Ca2+ antagonists.

Authors:  C Cauvin; S Lukeman; J Cameron; O Hwang; K Meisheri; H Yamamoto; C van Breemen
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Differential effects of the calcium entry blocker D 600 on contractions of rat and guinea-pig aortas, elicited by various alpha-1 adrenoceptor agonists.

Authors:  J J Beckeringh; M J Thoolen; A de Jonge; B Wilffert; P B Timmermans; P A van Zwieten
Journal:  J Pharmacol Exp Ther       Date:  1984-05       Impact factor: 4.030

10.  Sarcoplasmic reticulum and excitation-contraction coupling in mammalian smooth muscles.

Authors:  C E Devine; A V Somlyo; A P Somlyo
Journal:  J Cell Biol       Date:  1972-03       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.